BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-881@pharmaconomics
DTSTAMP:20260707T041756Z
DTSTART;VALUE=DATE:20260527
DTEND;VALUE=DATE:20260528
SUMMARY:TGTX Phase 3 — BRIUMVI (ublituximab-xiiy)
DESCRIPTION:Phase 3 trial results for BRIUMVI (ublituximab-xiiy) in relapsing forms of multiple sclerosis (RMS) are due May 27\, 2026. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1001316/000143774926018586/tgtx20260527_8k.htm\n\nTrack it: https://pharmaconomics.com/e/881
URL:https://pharmaconomics.com/e/881
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:TGTX catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR